Biotech Values

[DewDiligence]

ANDS—In what appears to be another instance of Zebra’s Law, ANDS is resuscitating ANA773, the TLR7 modulator for HCV that has been lying fallow for the past two years:

http://finance.yahoo.com/news/Anadys-Pharmaceuticals-prnews-3038064566.html?x=0&.v=1

The Company is preparing to commence during the second quarter a 28-day study of ANA773 in combination with ribavirin, and may test ANA773 as triple therapy in combination with ribavirin and a DAA in subsequent cohorts. Anadys intends to conduct this Phase IIa study of ANA773 in Europe and expects that up to approximately 75 patients will participate in the trial, including approximately 20 patients planned for the first two cohorts with ribavirin. Anadys expects to receive Week 4 viral load data for these first two cohorts in the fourth quarter of 2011.